CAMBRIDGE, Massachusetts, March 23, 2021 (GLOBE NEWSWIRE) – Solid Biosciences Inc., (NASDAQ: SLDB), a life science company focused on advancing significant therapies for Duchenne muscular dystrophy (Duchenne), today announced the closure of its subscribed public offering of 25,000,000 of its common shares at a public offering price of $ 5.75 per share, including 3,260,869 shares sold in accordance with the total exercise of the subscriber’s option to purchase additional shares. The gross proceeds from the sale of the shares, before deducting subscription discounts and commissions and offering expenses, were approximately $ 143.8 million.
Jefferies, SVB Leerink and Piper Sandler acted as joint managers for the bid management. Chardan served as the lead manager of the offer.
The shares were offered in accordance with an effective offshore registration statement that was filed with the Securities and Exchange Commission (“SEC”) on March 13, 2019, and declared effective by the SEC on March 19, 2019.
This offer was made only through a prospectus and prospectus supplement that was part of the registration statement. A final supplement to the related prospectus and describing the terms of the offer has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the supplement to the final prospectus and accompanying prospectus can also be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by calling (877) 821 -7388, or by email at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by calling (800) 808-7525, extension 6105, or by email at [email protected]; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by phone (800) 747-3924 or by email at [email protected].
This press release must not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor should there be any sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification. under the securities laws of any state or jurisdiction.
About solid biosciences
Solid Biosciences is a biological sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Focused on the disease and founded by a family directly affected by Duchenne, our mandate is simple, yet comprehensive – to work to treat the disease at its core by correcting the underlying mutation that causes Duchenne with our main candidate for gene therapy, SGT-001.
Investor contact:
David Carey
FINN Partners
212-867-1768
[email protected]
Media contact:
Erich Sandoval
FINN Partners
917-497-2867
[email protected]
